- Home
- SBGI vs SYRE Comparison
SBGI vs SYRE Comparison
Compare SBGI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- SYRE
- Stock Information
- Founded
- SBGI 1986
- SYRE 2013
- Country
- SBGI United States
- SYRE United States
- Employees
- SBGI N/A
- SYRE N/A
- Industry
- SBGI Broadcasting
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- SYRE Health Care
- Exchange
- SBGI Nasdaq
- SYRE Nasdaq
- Market Cap
- SBGI 956.9M
- SYRE 1.1B
- IPO Year
- SBGI 1995
- SYRE 2016
- Fundamental
- Price
- SBGI $14.36
- SYRE $17.38
- Analyst Decision
- SBGI Buy
- SYRE Buy
- Analyst Count
- SBGI 6
- SYRE 5
- Target Price
- SBGI $20.08
- SYRE $55.00
- AVG Volume (30 Days)
- SBGI 671.2K
- SYRE 490.8K
- Earning Date
- SBGI 08-06-2025
- SYRE 08-05-2025
- Dividend Yield
- SBGI 6.97%
- SYRE N/A
- EPS Growth
- SBGI N/A
- SYRE N/A
- EPS
- SBGI 0.74
- SYRE N/A
- Revenue
- SBGI $3,481,000,000.00
- SYRE N/A
- Revenue This Year
- SBGI N/A
- SYRE N/A
- Revenue Next Year
- SBGI $9.59
- SYRE N/A
- P/E Ratio
- SBGI $19.36
- SYRE N/A
- Revenue Growth
- SBGI 8.11
- SYRE N/A
- 52 Week Low
- SBGI $11.89
- SYRE $10.91
- 52 Week High
- SBGI $18.46
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- SBGI 52.40
- SYRE 57.01
- Support Level
- SBGI $13.39
- SYRE $15.73
- Resistance Level
- SBGI $15.43
- SYRE $17.42
- Average True Range (ATR)
- SBGI 0.68
- SYRE 0.89
- MACD
- SBGI 0.04
- SYRE 0.07
- Stochastic Oscillator
- SBGI 69.77
- SYRE 86.50
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.